natgillin/translations-raw huggingface dataset:
- Medicines that treat fungal infections, such as itraconazole, ketoconazole, and posaconazole - Medicines used to treat bacterial infections (antibiotics) such as erythromycin, clarithromycin, and rifampicin - Allergy medicines such as fexofenadine and ranolazine - Steroids used to reduce inflammation or treat a number of different diseases of the immune system - Medicines used to treat epilepsy or fits such as phenytoin, carbamazepine, and phenobarbital - Herbal preparations containing St. John's Wort (Hypericum perforatum), sometimes used for treating depression or depression-related conditions such as anxiety - Medicines used to thin the blood, such as warfarin - Medicines to treat high blood pressure or other heart conditions, such as aliskiren, ambrisentan, 
- Zdravila za zdravljenje glivičnih okužb, kot so itrakonazol, ketokonazol in posakonazol - Zdravila za zdravljenje bakterijskih okužb (antibiotiki), kot so eritromicin, klaritromicin in rifampicin - Zdravila proti alergijam, kot sta feksofenadin in ranolazin - Steroidi, ki se uporabljajo za zmanjšanje vnetja ali zdravljenje številnih različnih bolezni imunskega sistema - Zdravila za zdravljenje epilepsije ali epileptičnih napadov, kot so fenitoin, karbamazepin in fenobarbital - Pripravki zeliščnega izvora, ki vsebujejo šentjanževko (Hypericum perforatum), ki se včasih uporabljajo za zdravljenje depresije ali z depresijo povezanih stanj, kot je tesnobnost - Zdravila, ki se uporabljajo za redčenje krvi, kot je varfarin - Zdravila za zdravljenje visokega krvnega tlaka ali drugih bolezni srca, kot so aliskiren,
The recommended dose of COMETRIQ is 140 mg once daily, taken as one 80 mg orange capsule and three 20 mg grey capsules. 
Priporočeni odmerek zdravila COMETRIQ je 140 mg enkrat na dan, ki se jemlje kot ena 80 mg oranžna kapsula in tri 20 mg sive kapsule.
How to store COMETRIQ 6. 
Shranjevanje zdravila COMETRIQ 6.
In rats, cabozantinib caused postimplantation loss, foetal oedema, cleft palate/lip, dermal aplasia and kinked or rudimentary tail. 
Pri podganah je kabozantinib povzročil izgubo po vsaditvi, edeme ploda, razcepljeno nebo/zajčjo ustnico, dermalno aplazijo in upognjen ali nerazvit rep.
An oral examination should be performed prior to initiation of cabozantinib and periodically during cabozantinib therapy. 
Pred uvedbo kabozantiniba je treba opraviti pregled ustne votline, ki ga je treba v času zdravljenja s kabozantinibom periodično ponavljati.
Cabozantinib is not recommended for use in patients with severe hepatic impairment as safety and efficacy have not been established in this population. 
Uporaba kabozantiniba se ne priporoča pri bolnikih s hudo jetrno okvaro, saj varnost in učinkovitost pri tej populaciji nista bili dokazani.
Serious GI perforations and fistulas, sometimes fatal, and intra-abdominal abscesses have been observed with cabozantinib. 
Pri uporabi kabozantiniba so opazili resne gastrointestinalne perforacije in fistule, ki so včasih bile smrtne, ter intraabdominalne abscese.
• Swelling, pain in your hands and feet, or shortness of breath. 
• oteklina, bolečina v dlaneh in stopalih ali kratka sapa.
Adverse reactions such as fatigue and weakness have been associated with cabozantinib. 
Z uporabo kabozantiniba so povezani neželeni učinki, kot sta utrujenost in šibkost.
Administration of the strong CYP3A4 inducer rifampicin (600 mg daily for 31 days) to healthy volunteers increased cabozantinib clearance (4.3-fold) and decreased single-dose plasma cabozantinib exposure (AUC) by 77%. 
Dajanje močnega induktorja CYP3A4 rifampicina (600 mg na dan 31 dni) zdravim prostovoljcem je povzročila povečan očistek kabozantiniba (za 4,3-krat) in zmanjšano izpostavljenost kabozantinibu v plazmi po enem odmerku (AUC) za 77 %.
Cabozantinib was metabolized in vivo. 
Kabozantinib se in vivo presnavlja.
Therefore co-administration of strong CYP3A4 inhibitors (e.g., ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice) with cabozantinib should be approached with caution. 
Zato je pri sočasni uporabi močnih zaviralcev CYP3A4 (npr. ritonavirja, itrakonazola, eritromicina, klaritromicina, soka grenivke) s kabozantinibom potrebna previdnost.
Infections and infestations abscess (including visceral, skin, tooth), pneumonia, folliculitis, fungal infection (including skin, oral, genital) 
Infekcijske in parazitske bolezni absces (vključno z visceralnim, kožnim, zobnim), pljučnica, folikulitis, glivična okužba (vključno s kožno, oralno, genitalno)
one orange 80 mg + one grey 20 mg 
ena oranžna 80 mg + ena siva 20 mg
The hard capsules are grey with “XL184 20mg” printed in black on the body of the capsule. 
Trde kapsule so sive s črnim napisom "XL184 20mg" na telesu kapsule.
• 140 mg (1 orange 80 mg capsule and 3 grey 20 mg capsules) 
• 140 mg (1 oranžna 80 mg kapsula in 3 sive 20 mg kapsule)
Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES) has been observed with cabozantinib. 
Sindrom reverzibilne posteriorne levkoencefalopatije Pri uporabi kabozantiniba so opazili sindrom reverzibilne posteriorne levkoencefalopatije (RPLS, Reversible Posterior Leukoencephalopathy Syndrome), znan tudi kot sindrom posteriorne reverzibilne encefalopatije (PRES, Posterior Reversible Encephalopathy Syndrome).
• Abscess (collection of pus, with swelling and inflammation) in the abdomen or pelvis area or in your teeth/gums 
• abscesi (kopičenje gnoja z oteklostjo in vnetjem) v trebuhu ali predelu medenice ali zobeh/dlesnih
Package leaflet inside pouch. 
Navodilo za uporabo je znotraj zgibanke.
The most common serious adverse reactions associated with cabozantinib are pneumonia, mucosal inflammation, hypocalcaemia, dysphagia, dehydration, pulmonary embolism, and hypertension. 
Najbolj pogosti resni neželeni učinki, povezani s kabozantinibom, so pljučnica, vnetje sluznice, hipokalciemija, disfagija, dehidracija, pljučna embolija in hipertenzija.
• Reduced thyroid activity; symptoms can include: tiredness, weight gain, constipation, feeling cold and dry skin 
• zmanjšana aktivnost ščitnice; simptomi lahko vključujejo: utrujenost, zvišanje telesne mase,
A replacement sample will be requested if an original sample fails during the PCR quality or the Sanger sequencing tests. 
Če izvirni vzorec ne bo ustrezen za test kakovosti po PCR ali določanje zaporedja po Sangerju, bo pridobljen nadomestni vzorec.
Therefore, administration of MRP2 inhibitors may result in increases in cabozantinib plasma concentrations. 
Zato lahko dajanje zaviralcev MRP2 povzroči povečanje koncentracije kabozantiniba v plazmi.
Metabolism and nutrition disorders decreased appetite, hypocalcaemia, hypophosphataemia, hyperbilirubinemia, hypokalaemia, hypomagnesaemia dehydration, hypoalbuminaemia 
Presnovne in prehranske motnje zmanjšan apetit, hipokalciemija, hipofosfatemija, hiperbilirubinemija, hipokaliemija, hipomagneziemija dehidracija, hipoalbuminemija
The hard capsules are orange with “XL184 80mg” printed in black on the body of the capsule. 
Trde kapsule so oranžne s črnim napisom "XL184 80mg" na telesu kapsule.
Administration of MRP2 inhibitors may result in increases in cabozantinib plasma concentrations. 
Dajanje zaviralcev MRP2 lahko povzroči povečanje koncentracij kabozantiniba v plazmi.
CYP3A4 inducers and inhibitors 
Zaviralci in induktorji CYP3A4
Ear and labyrinth disorders ear pain, tinnitus hypoacusis 
Ušesne bolezni, vključno z motnjami labirinta bolečine v ušesih, tinitus hipoakuzija
• 100 mg (1 orange 80 mg capsule and 1 grey 20 mg capsule) 
• 100 mg (1 oranžna 80 mg kapsula in 1 sive 20 mg kapsula)
Chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John's Wort [Hypericum perforatum]) with cabozantinib should therefore be avoided. 
Kronični sočasni uporabi močnih induktorjev CYP3A4 (npr. fenitoina, karbamazepina, rifampicina, fenobarbitala ali pripravkov zeliščnega izvora iz šentjanževke [Hypericum perforatum]) s kabozantinibom se je treba zato izogniti.
An increase from baseline in corrected QT interval by Fridericia (QTcF) of 10 - 15 ms on Day 29 (but not on Day 1) following initiation of cabozantinib treatment (at a dose of 140 mg qd) was observed in a controlled clinical study in cancer patients. 
V kontroliranih kliničnih študijah pri bolnikih z rakom so opazili zvišanje glede na izhodišče popravljenega intervala QT z metodo po Fridericiju (QTcF) 10 -15 ms na 29. dan (vendar ne na 1. dan) po uvedbi zdravljenja s kabozantinibom (odmerek 140 mg enkrat na dan).
• Chills, tremors 
• mrzlica, tresenje
There is a possibility your fertility could be affected by treatment with COMETRIQ. 
Obstaja možnost, da bo zdravilo COMETRIQ vplivalo na vašo plodnost.
• Pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. 
• bolečine v ustih, zobeh in/ali čeljustih, oteklost ali razjede v ustih, omrtvelost ali občutek teže v čeljustih ali zrahljanje zoba.
A multi-center, randomized double-blind study comparing cabozantinib (N = 219) with placebo (N = 111) was conducted in patients with unresectable locally advanced or metastatic MTC and documented radiographic disease progression within 14 months prior to study entry. 
Pri bolnikih z neizrezljivim, lokalno napredovalim ali metastatskim medularnim karcinomom ščitnice in z radiografsko dokumentiranim napredovanjem bolezni v roku 14 mesecev pred vstopom v študijo so opravili multicentrično, randomizirano, dvojno slepo študijo, v kateri so primerjali kabozantinib (N = 219) s placebom (N = 111).
Not applicable. 
če je mogoče.
• Blister, pain of the hands or soles of the feet, rash or redness of the skin, dry skin 
• mehurji, bolečine v dlaneh ali podplatih, izpuščaj ali rdečina kože, suha koža
For invasive dental procedures, cabozantinib treatment should be held at least 28 days prior to scheduled surgery, if possible. 
Zdravljenje s kabozantinibom je treba ustaviti vsaj 28 dni pred načrtovanim invazivnim zobozdravstvenim posegom, če je mogoče.
• Abnormal connection of the tissue in your trachea (airway), oesophagus, or lungs 
• nenormalne povezave tkiva v sapniku (dihalih), požiralniku ali pljučih
Skin and subcutaneous tissue disorders palmar-plantar erythrodysaesthesia syndrome, hair colour changes, rash, dry skin, alopecia, erythema hyperkeratosis, acne, blister, hair growth abnormal, skin exfolation, skin hypopigmentation skin ulcer, telangiectasia 
Bolezni kože in podkožja sindrom palmarnoplantarne eritrodisestezije, spremenjena barva las, izpuščaj, suha koža, alopecija, eritem hiperkeratoza, akne, mehurji, nenormalna rast las, luščenje kože, hipopigmentacija kože kožne razjede, telangiektazija
• Inflammation of the oesophagus; symptoms can include heartburn, chest pain, feeling sick, altered taste, bloating, belching and indigestion 
• vnetje požiralnika; simptomi lahko vključujejo zgago, bolečine v prsnem košu, siljenje na bruhanje, spremenjeno okušanje, napenjanje, spahovanje in prebavne motnje
Reproductive system and breast disorders amenorrhoea, vaginal haemorrhage 
Motnje reprodukcije in dojk amenoreja, vaginalna krvavitev
Concurrent administration of cabozantinib with the strong CYP3A4 inhibitor ketoconazole resulted in an increase in cabozantinib plasma exposure. 
Sočasna uporaba kabozantiniba z močnim zaviralcem CYP3A4, ketokonazolom, je povzročila povečanje izpostavljenosti kabozantinibu v plazmi.
Peel paper backing 
Odluščite papirno hrbtno plast
Palmar-plantar erythrodysaesthesia syndrome (PPES) has been observed with cabozantinib. 
Pri uporabi kabozantiniba so opazili sindrom palmarno-plantarne eritrodisestezije (PPES, Palmarplantar erythrodysaesthesia syndrome).
Concurrent administration of cabozantinib with the strong CYP3A4 inducer rifampicin resulted in a decrease in cabozantinib plasma exposure. 
Sočasna uporaba kabozantiniba z močnim induktorjem CYP3A4, rifampicinom, je povzročila zmanjšanje izpostavljenosti kabozantinibu v plazmi.
Events of venous thromboembolism and events of arterial thromboembolism have been observed with cabozantinib. 
Pri uporabi kabozantiniba so opazili dogodke venske trombembolije in dogodke arterijske trombembolije.
SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION 
E. SPECIFIČNE ZAHTEVE ZA IZPOLNITEV UKREPOV PO PRIDOBITVI POGOJNEGA DOVOLJENJA ZA PROMET Z ZDRAVILOM
• Redness, swelling or pain in the mouth or throat, difficulty in speaking, hoarseness 
• rdečina, oteklina ali bolečina v ustih ali žrelu, težave z govorjenjem, hripavost
Uncommon side effects (may affect 1 in 100 people) 
Občasni neželeni učinki (pojavijo se lahko pri 1 od 100 bolnikov)
• Pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth 
• bolečine v ustih, zobeh in/ali čeljustih, oteklost ali razjede v ustih, omrtvelost ali občutek teže v čeljustih ali zrahljanje zoba
• Generalised pain, chest or muscle pain, ear pain, ringing in ears 
• bolečine po vsem telesu, bolečine v prsnem košu ali mišicah, bolečine v ušesih, zvonjenje v ušesih
Dispensing instructions 
Navodila za dajanje
Investigations weight decreased, serum ALT, AST, and ALP increased, blood LDH increased, blood TSH increased, lymphopenia, neutropenia, thrombocytopenia blood creatinine phosphokinase increased activated partial thromboplastin time shortened, eosinophil count increased, platelet count increased 
Preiskave zmanjšanje telesne mase, zvišanje vrednosti ALT, AST in ALP v serumu, zvišanje vrednosti LDH v krvi, zvišanje vrednosti TSH v krvi, limfopenija, nevtropenija, trombocitopenija zvišanje vrednosti kreatinin-fosfokinaze v krvi skrajšani aktivirani delni tromboplastinski čas, zvišanje števila eozinofilcev, zvišanje števila trombocitov
21 x 20 mg capsules (60 mg/day dose for a 7-day supply) 28 day pack containing: 
21 x 20 mg kapsul (odmerek 60 mg/dan, zaloga za 7 dni) 28-dnevno pakiranje, ki vsebuje:
100 mg Dose 
100 mg odmerek
140 mg Dose 
140 mg odmerek
Vascular disorders hypertension hypotension, venous thrombosis, pallor, peripheral coldness arterial thrombosis Aneurysms and artery dissections 
Žilne bolezni hipertenzija hipotenzija, venska tromboza, bledica, periferni hlad arterijska tromboza anevrizme in disekcije arterij
Musculoskeletal and connective tissue disorders arthralgia, muscle spasms, pain in extremity musculoskeletal chest pain, osteonecrosis of jaw rhabdomyolysis 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva artralgija, mišični spazmi, bolečine v okončinah mišično-skeletne bolečine v prsnem košu, osteonekroza čeljusti rabdomioliza
Cabozantinib should be discontinued in patients who experience a GI perforation or a GI or non-GI fistula. 
Uporabo kabozantiniba je treba pri bolnikih, pri katerih se pojavi gastrointestinalna perforacija ali gastrointestinalna oz. ne-gastrointestinalna fistula, prekiniti.
Tell your doctor if any of these affect you. 
Če vas kar koli od tega zadeva, to povejte zdravniku.
• Stomach upset, including diarrhoea, nausea, vomiting, constipation, indigestion, and abdominal pain 
• razdražen želodec, vključno z drisko, slabostjo, bruhanjem, zaprtostjo, prebavnimi motnjami in bolečinami v trebuhu
Capsule content Microcrystalline cellulose Croscarmellose sodium Sodium starch glycolate Silica colloidal anhydrous Stearic acid 
Vsebina kapsule mikrokristalna celuloza premreženi natrijev karmelozat natrijev karboksimetilškrob brezvodni koloidni silicijev dioksid stearinska kislina
Nervous system disorders dysgeusia, headache, dizziness cerebrovascular accident, peripheral neuropathy, paraesthesia, ageusia, tremor ataxia, disturbance in attention, hepatic encephalopathy, loss of consciousness, speech disorder, posterior reversible encephalopathy syndrome 
Bolezni živčevja disgevzija, glavobol, omotica možganska kap, periferna nevropatija, parestezija, agevzija, tremor ataksija, motnje pozornosti, jetrna encefalopatija, izguba zavesti, motnje govora, sindrom posteriorne reverzibilne levkoencefalopatije
• Symptoms including pain in the abdomen, nausea, vomiting, constipation, or fever. 
• Simptomi, ki vključujejo bolečine v trebuhu, slabost, bruhanje, zaprtost ali zvišano telesno temperaturo.
Renal and urinary disorders proteinuria, dysuria, haematuria renal failure acute 
Bolezni sečil proteinurija, dizurija, hematurija akutna ledvična odpoved
NAME OF THE MEDICINAL PRODUCT COMETRIQ 20 mg hard capsules 
IME ZDRAVILA COMETRIQ 20 mg trde kapsule
Each 100 mg daily dose contains a combination of one grey 20 mg capsule and one orange 80 mg capsule. 
En 100 mg dnevni odmerek vsebuje kombinacijo ene sive 20 mg kapsule in ene oranžne 80 mg kapsule.
EU/1/13/890/002 7 x 20 mg and 7 x 80 mg capsules (100 mg/day dose for a 7-day supply) EU/1/13/890/003 21 x 20 mg and 7 x 80 mg capsules (140 mg/day dose for a 7-day supply) EU/1/13/890/005 56 capsules (4 blister cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose for 28 day supply) 
EU/1/13/890/002 7 x 20 mg in 7 x 80 mg kapsul (odmerek 100 mg/dan, zaloga za 7 dni) EU/1/13/890/003 21 x 20 mg in 7 x 80 mg kapsul (odmerek 140 mg/dan, zaloga za 7 dni) EU/1/13/890/005 56 kapsul (4 pretisne zgibanke z: 7 x 20 mg in 7 x 80 mg) (odmerek
• Haemorrhoids 
• zamegljen vid
Effective methods of contraception should be used by male and female patients and their partners during therapy, and for at least 4 months after completing therapy. 
Med zdravljenjem in še vsaj 4 mesece po končanju terapije morajo tako bolniki in bolnice kot tudi njihovi partnerji uporabljati zanesljiv način kontracepcije.
Each daily dose is given in one row and contains three 20 mg capsules: 
Vsak dnevni odmerek je v eni vrsti in vsebuje tri 20 mg kapsule:
• Infection and inflammation in the lung, collapse of lung 
• okužbe in vnetje pljuč, sesedanje pljuč
Two non-conjugated metabolites (XL184-N-oxide and XL184 
Dva nekonjugirana presnovka (XL184-N-oksid in produkt cepitve XL184 amida), ki imata zaviralno učinkovitost na kinazo, ki je
Pack for the 140 mg daily dose 
Pakiranje s 140 mg dnevnim odmerkom
No dose adjustment is indicated when gastric pH modifying agents (i.e., PPIs, H2 receptor antagonists, and antacids) are co-administered with cabozantinib. 
Pri sočasni uporabi zdravil, ki spreminjajo vrednost pH v želodcu (tj. zaviralci protonske črpalke, antagonisti receptorjev H2 in antacidi) odmerka kabozantiniba ni treba prilagajati.
Pack for the 100 mg daily dose 
Pakiranje s 100 mg dnevnim odmerkom
Non-GI fistula should be ruled out as appropriate in cases of onset of mucositis after start of therapy. 
V primeru pojava mukozitisa po uvedbi terapije je treba ustrezno izključiti ne-gastrointestinalne fistule.
Each 140 mg daily dose contains a combination of three grey 20 mg capsules and one orange 80 mg capsule. 
En 140 mg dnevni odmerek vsebuje kombinacijo treh sivih 20 mg kapsul in ene oranžne 80 mg kapsule.
• Impaired hearing 
• nenormalna rast las
Titanium dioxide (E171) 
Ovojnica kapsule želatina črni železov oksid (E172) titanov dioksid (E171)
What COMETRIQ contains 
Kaj vsebuje zdravilo COMETRIQ
Table 1: Adverse reactions reported with cabozantinib 
Preglednica 1: Neželeni učinki, o katerih so poročali pri kabozantinibu Organski sistem po
How to take COMETRIQ 
Kako jemati zdravilo COMETRIQ
PHARMACEUTICAL FORM AND CONTENTS 60 mg Dose 28 day pack: 84 capsules (4 blister cards of 21 x 20 mg capsules) for the 60 mg daily dose for a 28 day supply. 
FARMACEVTSKA OBLIKA IN VSEBINA odmerek 60 mg 28-dnevno pakiranje: 84 kapsul (4 pretisne zgibanke z: 21 x 20 mg kapsulami) za odmerek 60 mg na dan, zaloga za 28 dni.
Caution should be used in patients receiving agents associated with ONJ, such as bisphosphonates. 
Pri bolnikih, ki prejemajo učinkovine, povezane z osteonekrozo čeljusti, kot so difosfonati, je potrebna previdnost.
Concomitant medicinal products 
Sočasna uporaba z drugimi zdravili
Cabozantinib treatment should be discontinued in patients with RPLS. 
Pri bolnikih z RPLS je treba z zdravljenje s kabozantinibom prenehati.
• Fungal infection that can be in the skin, mouth, or genitals 
• glivične okužbe kože, ust ali spolovil
COMETRIQ 20 mg hard capsules COMETRIQ 80 mg hard capsules 
COMETRIQ 20 mg trde kapsule COMETRIQ 80 mg trde kapsule
Respiratory, thoracic, and mediastinal disorders dysphonia, oropharyngeal pain non-gastrointestinal fistula (including tracheal, pneumomediastinu m, tracheooesophageal), pulmonary embolism, respiratory tract haemorrhage (including pulmonary, bronchial, tracheal), pneumonia aspiration atelectasis, pharyngeal oedema, pneumonitis 
Bolezni dihal, prsnega koša in mediastinalneg a prostora disfonija, orofaringealne bolečine ne-gastrointestinalna fistula (vključno s trahealno, pnevmomediastinumo m, traheoezofagealno), pljučna embolija, krvavitev v dihalih (vključno s pljuči, sapnicami, sapnikom), aspiracijska pljučnica atelektazija, faringealni edem, pnevmonitis
Gastrointestinal disorders diarrhoea, nausea, stomatitis, constipation, vomiting, abdominal pain, dyspepsia, dysphagia, glossodynia gastrointestinal perforation, gastrointestinal haemorrhage, pancreatitis, haemorrhoids, anal fissure, anal inflammation, cheilitis gastrointestinal fistula, oesophagitis 
Bolezni prebavil driska, navzea, stomatitis, konstipacija, bruhanje, bolečine v trebuhu, dispepsija, disfagija, glosodinija gastrointestinalna perforacija, gastrointestinalna krvavitev, pankreatitis, hemoroidi, analna fisura, analno vnetje, heilitis gastrointestinaln a fistula, ezofagitis
Caution is required when administering cabozantinib with agents that are strong CYP3A4 inhibitors. 
Pri uporabi kabozantiniba z učinkovinami, ki so močni zaviralci CYP3A4, je potrebna previdnost.
Pack for the 60 mg daily dose Each 60 mg daily dose contains three grey 20 mg capsules. 
Pakiranje s 60 mg dnevnim odmerkom En 60 mg dnevni odmerek vsebuje tri sive 20 mg kapsule.
EU/1/13/890/001 21 x 20 mg capsules (60 mg/day dose for a 7-day supply) EU/1/13/890/004 84 capsules (4 blister cards of 21 x 20 mg) (60 mg/day dose for a 28 day supply) 
EU/1/13/890/001 21 x 20 mg kapsule (odmerek 60 mg/dan, zaloga za 7 dni) EU/1/13/890/004 84 kapsul (4 pretisne zgibanke z 21 x 20 mg) (odmerek 60 mg/dan, zaloga za
Each daily dose is provided in one row and contains one 80 mg capsule and one 20 mg capsule: 
Vsak dnevni odmerek je v eni vrsti in vsebuje eno 80 mg kapsulo in eno 20 mg kapsulo:
Respiratory, thoracic, and mediastinal disorders dysphonia, oropharyngeal pain non-gastrointestinal fistula (including tracheal, pneumomediastinum, tracheo-oesophageal), pulmonary embolism, respiratory tract haemorrhage (including pulmonary, bronchial, tracheal), pneumonia aspiration atelectasis, pharyngeal oedema, pneumonitis 
Bolezni dihal, prsnega koša in mediastinalnega prostora disfonija, orofaringealne bolečine ne-gastrointestinalna fistula (vključno s trahealno, pnevmomediastinumom, traheo-ezofagealno), pljučna embolija, krvavitev v dihalih (vključno s pljuči, sapnicami, sapnikom), aspiracijska pljučnica atelektazija, faringealni edem, pnevmonitis
Pack for the 60 mg daily dose 21 x 20 mg capsules (60 mg/day dose for a 7-day supply) Each 60 mg daily dose contains three grey 20 mg capsules. 
Pakiranje s 60 mg dnevnim odmerkom 21 x 20 mg kapsul (odmerek 60 mg/dan, zaloga za 7 dni) En 60 mg dnevni odmerek vsebuje tri sive 20 mg kapsule.
Each 60 mg daily dose contains a combination of three grey 20 mg capsules. 
En 60 mg dnevni odmerek vsebuje tri sive 20 mg kapsule.
- have high blood pressure - have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall. 
- imate visok krvni tlak, - imate ali ste imeli anevrizmo (razširitev in oslabitev stene krvne žile) ali raztrganino v steni krvne žile, - imate drisko, - ste pred nedavnim izkašljevali krvi ali imeli znatno krvavitev, - ste imeli v zadnjem mesecu kirurški poseg (ali ga načrtujete), vključno z zobozdravstvenimi posegi,
The COMETRIQ 80 mg capsules contain cabozantinib (S)-malate equivalent to 80 mg of cabozantinib. 
Zdravilo COMETRIQ 80 mg kapsule vsebuje kabozantinib (S)-malat v količini, ki ustreza 80 mg kabozantiniba.
Hard capsules 20 mg 
trda kapsula 20 mg odmerek 60 mg